{"entity":{"id":"nct04910022","kind":"trial","name":"Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma","aka":[],"tldr":"A phase 1/2 trial of Temozolomide in glioma & glioblastoma, run by Nerviano Medical Sciences, active and no longer recruiting.","summary":"Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma is a phase 1/2 interventional study registered as NCT04910022 by Nerviano Medical Sciences, with 150 participants enrolled, started 2021-12-01 and due to reach its primary completion in 2027-05-30. Interventions recorded: NMS-03305293 and Temozolomide.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04910022","url":"https://clinicaltrials.gov/study/NCT04910022"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["temozolomide"],"companies":["nerviano-medical-sciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04910022","phase":"1/2","setting":"A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients With Recurrent Glioblastoma","sponsor":"Nerviano Medical Sciences","started":"2021-12-01","startedType":"actual","enrolled":150,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04910022/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}],"company":[{"id":"nerviano-medical-sciences","kind":"company","name":"Nerviano Medical Sciences","route":"/companies/nerviano-medical-sciences/"}]}}